• LAST PRICE
    73.0000
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    71.0000/ 1
  • Ask / Lots
    76.4900/ 1
  • Open / Previous Close
    75.5300 / 73.0000
  • Day Range
    Low 71.3400
    High 75.5600
  • 52 Week Range
    Low 38.7800
    High 89.3900
  • Volume
    312,862
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Monday's close: 75.51
TimeVolumeNUVL
09:32 ET257775.56
09:34 ET36775.3473
09:43 ET46275.03
09:48 ET10075.03
09:57 ET10074.96
09:59 ET10074.95
10:03 ET10075.27
10:08 ET10075.315
10:10 ET10075.32
10:12 ET30074.985
10:14 ET30074.91
10:15 ET421774.38
10:19 ET10074.34
10:28 ET20074.65
10:33 ET20074.8
10:35 ET20074.815
10:39 ET42075.1
10:44 ET10075.11
10:46 ET10075.105
10:50 ET30075.0025
10:53 ET10074.86
10:55 ET10074.97
11:02 ET10075.46
11:04 ET10075.24
11:06 ET30074.98
11:08 ET10074.98
11:09 ET10074.985
11:13 ET10074.84
11:15 ET14774.89
11:18 ET10074.8
11:24 ET10074.62
11:31 ET20074.86
11:33 ET40074.52
11:36 ET14574.45
11:54 ET10074.19
11:56 ET20074.17
11:58 ET10074.21
12:02 ET30074.11
12:09 ET499073.6
12:12 ET110073.33
12:14 ET10073.29
12:16 ET24973.25
12:20 ET34573.215
12:23 ET10073.28
12:30 ET80073.38
12:36 ET21372.91
12:38 ET297973.03
12:39 ET220072.52
12:41 ET40072.5
12:43 ET100072.48
12:45 ET873472.56
12:48 ET196572.39
12:50 ET40072.19
12:52 ET20072.39
12:54 ET30072.58
12:56 ET10072.73
12:59 ET10072.54
01:06 ET127972.49
01:12 ET30072.435
01:15 ET38772.435
01:17 ET80072.39
01:19 ET10072.29
01:21 ET54072.29
01:24 ET39272.34
01:26 ET10072.22
01:28 ET30072.25
01:30 ET23972.07
01:32 ET89872.14
01:33 ET20072.04
01:37 ET48372.03
01:39 ET130072.315
01:42 ET90072.085
01:44 ET59972.17
01:48 ET10072.255
01:50 ET10072.255
01:51 ET223172.04
01:53 ET1517071.48
01:55 ET150071.73
01:57 ET385372.0006
02:02 ET84972.1876
02:04 ET335772.24
02:06 ET70072.2138
02:09 ET20072.16
02:11 ET10072.17
02:13 ET30072.05
02:15 ET20072.03
02:24 ET30071.79
02:29 ET30471.835
02:33 ET20071.895
02:36 ET90072.115
02:38 ET10072.11
02:40 ET90172.315
02:44 ET10072.33
02:45 ET98472.19
02:47 ET10072.135
02:49 ET10072.09
02:51 ET20072.215
02:54 ET55072.175
02:56 ET80072.01
03:00 ET60071.87
03:03 ET20071.76
03:05 ET10071.76
03:09 ET159671.95
03:14 ET30971.77
03:16 ET10071.815
03:18 ET30971.9573
03:20 ET20072.09
03:21 ET10072.16
03:23 ET50072.095
03:25 ET31772
03:27 ET60071.985
03:30 ET94971.96
03:34 ET70071.99
03:36 ET46872.0799
03:39 ET133571.82
03:43 ET10071.98
03:45 ET154771.82
03:48 ET20071.735
03:50 ET20071.66
03:52 ET55071.63
03:54 ET525271.92
03:56 ET951572.065
03:57 ET883272.26
03:59 ET8499473
Data delayed at least 15 minutes.
No documents available
0 New Today
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesNUVL
Nuvalent Inc
4.9B
-30.3x
---
United StatesBBIO
BridgeBio Pharma Inc
4.7B
-7.7x
---
United StatesIBRX
Immunitybio Inc
4.3B
-5.9x
---
United StatesRNA
Avidity Biosciences Inc
4.4B
-13.2x
---
United StatesKRYS
Krystal Biotech Inc
5.2B
94.4x
---
United StatesSMMT
Summit Therapeutics Inc
5.7B
-45.5x
---
As of 2024-07-03

Company Information

Nuvalent, Inc. is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer. It develops small molecules that have the potential to overcome resistance, minimize adverse events, address brain metastases and drive more durable responses. It is advancing a robust pipeline with investigational candidates for ROS1-positive, ALK-positive, and HER2-positive non-small cell lung cancer, and multiple discovery-stage research programs. Its product candidate, NVL-520, is being developed for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC). NVL-520 is a novel ROS1-selective inhibitor. Its product candidate, NVL-655, is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC. LC. NVL-655 is a brain-penetrant ALK-selective inhibitor. Its product candidate, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor.

Contact Information

Headquarters
One Broadway, 14th FloorCAMBRIDGE, MA, United States 02142
Phone
857-357-7000
Fax
302-655-5049

Executives

Non-Executive Independent Chairman of the Board
Anna Protopapas
President, Chief Executive Officer, Director
James Porter
Chief Financial Officer, Treasurer
Alexandra Balcom
Chief Development Officer
Darlene Noci
Chief Medical Officer
Christopher Turner

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$4.9B
Revenue (TTM)
$0.00
Shares Outstanding
64.6M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
---
EPS
$-2.41
Book Value
$10.94
P/E Ratio
-30.3x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.